CAJ | 학술논문

目的：探讨新辅助化疗联合肿瘤细胞减灭术及术后腹腔热灌注治疗晚期卵巢癌的临床疗效。方法：分析郑州人民医院从2009年4月至2012年7月收治的60例晚期卵巢癌的患者，分为两组，研究组患者术前采取新辅助化疗联合肿瘤细胞减灭术及术后腹腔热灌注辅助化疗2次（顺铂80 mg），术后给予TC/TP方案化疗，对照组采取常规肿瘤细胞减灭术+术后TC/TP方案化疗，比较两组患者在手术时间、出血量、腹水量、术后化疗疗程、疗效、复发与死亡、生存率等数据的差异。结果：研究组患者在术中的各项疗效指标优于对照组，且有统计学显著性差异（P<0.05），临床治疗有效率高于对照组。结论：在临床上对于晚期卵巢癌患者采取术前新辅助化疗联合肿瘤细胞减灭术术后腹腔热灌注辅助化疗，对于患者的疗效较常规的方法有较大的提高，值得在临床上进行推广。
목적：탐토신보조화료연합종류세포감멸술급술후복강열관주치료만기란소암적림상료효。방법：분석정주인민의원종2009년4월지2012년7월수치적60례만기란소암적환자，분위량조，연구조환자술전채취신보조화료연합종류세포감멸술급술후복강열관주보조화료2차（순박80 mg），술후급여TC/TP방안화료，대조조채취상규종류세포감멸술+술후TC/TP방안화료，비교량조환자재수술시간、출혈량、복수량、술후화료료정、료효、복발여사망、생존솔등수거적차이。결과：연구조환자재술중적각항료효지표우우대조조，차유통계학현저성차이（P<0.05），림상치료유효솔고우대조조。결론：재림상상대우만기란소암환자채취술전신보조화료연합종류세포감멸술술후복강열관주보조화료，대우환자적료효교상규적방법유교대적제고，치득재림상상진행추엄。
Objective:We aimed to investigate the clinical efficacy of neoadjuvant chemotherapy combined with cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP) after the operation of patients with advanced ovarian cancer. Meth-ods:Analysis of 60 patients with advanced ovarian cancer was performed at the Zhengzhou People's Hospital from April 2009 to July 2012. The patients were divided into two groups, namely, the research and control groups. The research group was treated with neoadju-vant chemotherapy combined with cytoreductive surgery and IHCP twice (cisplatin at 80 mg), and subsequently, with chemotherapy (TC/TP). The control group underwent primary cytoreductive surgery and chemotherapy (TC/TP). We compared the differences be-tween the two groups in terms of the following parameters:operation time, bleeding volume, volume of ascites, and postoperative che-motherapy. Results:The treatments in the research group were more efficient than those performed on the control group in terms of all the intraoperative indicators, and the difference between the two groups was statistically significant (P<0.05). Conclusion:Compared with conventional methods, the neoadjuvant chemotherapy combined with cytoreductive surgery and IHCP after operation was more ef-fective for patients with advanced ovarian cancer. Thus, neoadjuvant chemotherapy combined with cytoreductive surgery and IHCP af-ter operation can be applied in clinical settings.